Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $18.6400 (-2.82%) ($17.6200 - $19.2100) on Thu. May. 7, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 8.85% (three month average) | RSI | 74 | Latest Price | $18.6400(-2.82%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 9.7% a day on average for past five trading days. | Weekly Trend | TGTX advances 14.2% a week on average for past two weeks. | Market Behavior | Growth stock rally for large cap. Value stock rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(63%) ARKG(57%) ARKK(54%) IBB(54%) IWO(53%) | Factors Impacting TGTX price | TGTX will decline at least -4.425% in a week (0% probabilities). VIXM(-34%) VXX(-32%) UUP(-15%) TLT(-1%) IGOV(-1%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -4.425% (StdDev 8.85%) | Hourly BBV | 0 () | Intraday Trend | -1.6% | | | |
|
5 Day Moving Average | $15.65(19.11%) | 10 Day Moving Average | $14.15(31.73%) | 20 Day Moving Average | $12.81(45.51%) | To recent high | -2.8% | To recent low | 161.1% | Market Cap | $2.361b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |